financetom
Business
financetom
/
Business
/
Conagra Brands Likely to See In-Line Fiscal Q1 Results, Potential Risk to Fiscal Q2 Consensus, Morgan Stanley Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Conagra Brands Likely to See In-Line Fiscal Q1 Results, Potential Risk to Fiscal Q2 Consensus, Morgan Stanley Says
Sep 24, 2025 8:00 AM

10:41 AM EDT, 09/24/2025 (MT Newswires) -- Conagra Brands ( CAG ) is projected to report fiscal Q1 results in line with expectations and maintain its fiscal 2026 guidance, but the food company faces a potential cut to fiscal Q2 consensus estimates, Morgan Stanley said in a Wednesday note.

Conagra is set to release its fiscal Q1 results on Oct. 1, and Morgan Stanley said it expects the period's organic sales growth to improve from fiscal Q4, backed by better scanner sales against easy comparisons.

Fiscal Q2 consensus forecasts, however, "may need to come down" due to "sticky" input cost inflation and slowing scanner sales trends, said the investment firm.

Morgan Stanley lowered its fiscal 2026 earnings per share estimate for Conagra to $1.71 from $1.73.

Morgan Stanley raised its price target on Conagra's stock to $21 from $20, with an equal-weight rating.

Price: 18.28, Change: +0.07, Percent Change: +0.41

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Jones Lang LaSalle Offers Steady Growth Outlook, UBS Says
Jones Lang LaSalle Offers Steady Growth Outlook, UBS Says
Nov 17, 2025
02:58 PM EST, 11/17/2025 (MT Newswires) -- Jones Lang LaSalle ( JLL ) is set to benefit from improving industry tailwinds amid attractive valuation after its Q3 results, UBS Securities said in a Sunday note. The report pointed to an outlook downgrade for its Real Estate Management Services segment for the next several quarters while Q3 margin expansion disappointed, similar...
Liberty Defense Up Near 14% On Contract Win for Multiple HEXWAVE Walkthrough Screening Systems From a U.S. State Capitol Complex
Liberty Defense Up Near 14% On Contract Win for Multiple HEXWAVE Walkthrough Screening Systems From a U.S. State Capitol Complex
Nov 17, 2025
03:04 PM EST, 11/17/2025 (MT Newswires) -- Liberty Defense Holdings ( LDDFF ) shares were up near 14% on Monday after it received a competitive bid award for three HEXWAVE walkthrough screening systems at a U.S. State Capitol complex in the Northeast. The company said the systems will support security screening for officials, employees, and visitors across two high-traffic buildings....
Target May Tighten 2025 Outlook as Q3 Comps Stay Weak, Oppenheimer Says
Target May Tighten 2025 Outlook as Q3 Comps Stay Weak, Oppenheimer Says
Nov 17, 2025
02:46 PM EST, 11/17/2025 (MT Newswires) -- Target ( TGT ) is likely to post soft Q3 on Wednesday with comparable sales down about 2% and could narrow its fiscal 2025 earnings per share guidance toward the low end of its $7 to $9 range, Oppenheimer said Monday in a pre-results report. Oppenheimer said it added conservatism to its Q4...
Jazz Pharmaceuticals Stock Rallies On Positive Phase 3 Trial Results for Ziihera In Advanced Gastroesophageal Cancer
Jazz Pharmaceuticals Stock Rallies On Positive Phase 3 Trial Results for Ziihera In Advanced Gastroesophageal Cancer
Nov 17, 2025
Jazz Pharmaceuticals Plc ( JAZZ ) shares are popping on Monday following the company’s positive results of its Phase 3 HERIZON-GEA-01 trial, which assessed Ziihera in combination with chemotherapy, with or without the PD-1 inhibitor Tevimbra, as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). What Happened: When compared to the control group that received trastuzumab...
Copyright 2023-2025 - www.financetom.com All Rights Reserved